Quick Summary of Cardinal’s Q3 FY26 Results

This week, we’re stepping away from our usual personal finance topics to take a brief look at Cardinal Health’s latest earnings release.

As employees, you naturally have access to insights that go well beyond what’s shared publicly. Still, an outside perspective on the publicly available information can be useful—especially if you haven’t had time to read the earnings release or listen to the call.

While there’s no substitute for hearing leadership directly, this summary is meant to give you a clear, simple view of the quarter’s results and the themes shaping the company’s long‑term direction.

Quick Earnings Summary

Cardinal Health delivered another strong quarter, continuing the momentum of the past few years. Revenue grew 11 percent to ~61 billion dollars, driven by broad‑based demand across Pharmaceutical and Specialty Solutions and the Other growth businesses. Gross profit rose 18 percent, and enterprise operating earnings increased 18 percent to 956 million dollars.

Non-GAAP EPS grew 35 percent to $3.17, supported by strong operational performance, discrete tax benefits, and continued share repurchases. The company raised full‑year non-GAAP EPS guidance to $10.70-$10.80, representing 30-31 percent growth for the year.

Pharmaceutical and Specialty Solutions segment profit was up 18 percent. Specialty revenue grew more than 20 percent, and oncology grew more than 30 percent. The company reaffirmed that Specialty revenue is on track to exceed 50 billion dollars this fiscal year.

GMPD delivered stable underlying performance, with Cardinal Health brand products growing more than 5 percent. Tariffs remain a headwind, but the business continues to execute its improvement plan.

The Other growth businesses—at Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics—delivered another standout quarter, with revenue up 31 percent and profit up 34 percent. Demand remains strong across all three businesses.

Free cash flow was a highlight, with 1.7 billion dollars generated in the quarter and full‑year guidance raised to 3.3 to 3.7 billion dollars.

Initial Market Reaction

Despite the strong operational results and raised full‑year guidance, the stock finished the day down 4.84 percent. Short‑term market reactions can be influenced by many factors—sector moves, shifting short-term expectations, or broader macro headlines—and don’t always reflect the underlying trajectory of the business. For employees who follow the stock closely, it’s simply a reminder that daily price movements often diverge from long‑term fundamentals.

Taking a step back however, the 10-year chart shows the stock well off the 2020 lows and more than double the 10-year average price of $81.71:

Inside the Q&A: Management’s Perspective

The Q&A portion of the call offered helpful clarity on several topics employees often ask about. Here are the themes that stood out.

IRA Pricing, Revenue Mix, and Fee for Service Economics

Leadership emphasized that while IRA (Inflation Reduction Act)‑related list price changes affect revenue optics, they do not change the underlying economics of distribution. Cardinal renegotiated contracts ahead of these changes and expects to maintain the fees it receives for the services it provides.

GLP 1 revenue grew more than 30 percent but moderated from prior quarters. GLP 1s added 6 percentage points to revenue growth, offset by a similar 6‑point headwind from IRA WAC adjustments. Leadership reiterated that GLP 1s are “empty calorie” dollars—large revenue, minimal profit.

Specialty Momentum and the Navista Impairment

Specialty continues to be one of the company’s strongest engines, growing more than 20 percent overall and more than 30 percent in oncology.

The Navista goodwill impairment was described as Cardinal‑specific, tied to a shift in strategy toward equity‑based MSO models rather than a change in the broader oncology market. Leadership reaffirmed confidence in the MSO strategy and the long‑term growth of Specialty.

Distribution Contract Onboarding (ION, GIA, Solaris)

Cardinal confirmed that Solaris distribution volumes are now ramping into the Pharma network. While the impact to FY26 is small due to timing, it is a positive contributor heading into FY27.

Tariff Refund Mechanics

The Supreme Court ruling on IEEPA tariffs could lead to refunds. Cardinal has paid roughly 200 million dollars in these tariffs. Because some of the cost was passed through to customers, the potential net benefit to Cardinal is estimated at about half—around 100 million dollars.

No refund has been recognized in results or guidance due to uncertainty around timing and process.

2027 Puts and Takes

Leadership reiterated confidence in the long‑term EPS growth target of 12 to 14 percent. Key drivers include:

• Strong demand and demographic tailwinds
• Continued Specialty expansion
• Strength across the Other growth businesses
• Ongoing cost discipline and tax optimization

Management expects operational strength and disciplined capital allocation to support long‑term growth.

Energy, Input Costs, and GMPD

Fuel and oil‑related cost pressures are rising, but leadership emphasized that today’s environment is far more manageable than the broad inflationary shock of 2022. Exam gloves are seeing notable cost increases, but they represent less than 5 percent of Cardinal‑branded product.

GMPD remains on track with its improvement plan, and leadership reaffirmed confidence in its long‑term profit outlook.

The Longer View

One theme came through clearly: Cardinal’s leadership is focused on building a durable, resilient enterprise that can perform through change.

Across the call, several long‑term signals stood out:

• Three years of sustained investment in infrastructure, automation, technology, and people are now showing up in record service levels and improved capacity.
• Specialty is becoming a true flywheel, with MSOs, biopharma services, Nuclear, and at Home Solutions creating some cross business synergies.
• The Other growth businesses are benefiting from secular trends—care shifting to the home, growth in theranostics, and the need for logistics efficiency.
• Cash generation remains a strength, supporting investment, debt reduction, and shareholder returns.
• The company is positioned for FY27 and beyond, with leadership reiterating confidence in long‑term targets despite a dynamic regulatory and macro environment.

Taken together, the quarter reinforced a simple message: the company’s strategy is working, and the foundations for future growth are already in place.

What This Means for You

Stronger Results Reinforce Long Term Value

With revenue, earnings, and guidance all moving higher, the company’s financial momentum supports long‑term share value—especially relevant for those planning around LTI decisions.

Execution Across All Segments Builds Stability

Pharma, Specialty, GMPD, and the Other growth businesses all contributed to the quarter. That kind of broad‑based strength creates a more resilient business over time.

Capital Allocation Remains Disciplined

Share repurchases, debt reduction, and targeted M&A reflect a steady, long‑term approach rather than chasing short‑term trends.

Staying Informed Helps You Plan Ahead

Understanding where the company is headed can help you make better decisions about retirement planning, equity comp, and your broader financial strategy.

We’ll return to our usual financial topics next week.

Schedule a mtg Cardinal: If you ever want to talk through your Cardinal benefits or your own situation, you’re welcome to schedule a relaxed Q&A. No cost, no pressure, and no expectation to meet again — just a chance to talk things through. CLICK HERE TO SCHEDULE 

Take care and, as always, stay the course.